In this study, we develop a macrophage-specific synthetic promoter for the therapeutic application of adiponectin (APN), an antiatherogenic gene.

Xbrane Biosciences says its Lemo and Rhamex technologies enable the optimized production of both routine and difficult targets in E. coli.